Fewer than a third of commercially insured US adults who started a GLP-1 drug for obesity were still taking it consistently a year later, an analysis of 201,229 claims records has found. About 64% fell into one of three discontinuation patterns: stopping almost immediately, stopping within a few months, or tailing off later in the … Read more
Just under 17% of 10- to 17-year-olds who started a GLP-1 drug were diagnosed with a nutritional deficiency or a related complication within the following year, an analysis of US insurance claims has found. Most of those diagnoses were vitamin D deficiency. Fewer than a quarter of the teenagers saw anyone for nutrition counselling within … Read more
A five-day fast produced a fall in body mass index that was still partly present twelve weeks later, and the mix of bacteria in a person’s gut beforehand helped predict how much of it they kept, according to a randomised trial published on 16 September in Genome Medicine. The study involved 38 healthy adults under … Read more
A dual GLP-1/GIP receptor agonist made by a Chinese biotech produced up to 18.3% weight loss over 24 weeks in a placebo-controlled phase 2 trial, according to results published on 17 September in Diabetes, Obesity and Metabolism. The drug, BGM0504, acts on the same two gut-hormone receptors as tirzepatide. The trial was small, at 120 … Read more
One of the open questions about GLP-1 drugs is whether they are a good idea in people who are already frail — older, carrying several conditions, less able to absorb a period of appetite loss. A new analysis of the SELECT trial, published in JAMA Cardiology on 16 September 2026, sorted all 17,604 participants by … Read more
Berberine is sold online as a natural alternative to prescription weight-loss drugs, usually on evidence far thinner than the marketing. A randomised, double-blind, placebo-controlled trial published in Nutrients tested a fixed combination of berberine, white mulberry leaf extract and chromium picolinate in 93 Greek adults with obesity over 12 weeks, and found real differences against … Read more
The FDA on 15 September 2026 told consumers not to buy or use two products sold for weight loss, LUZE Fit Intensity and Beauty 911, after its laboratory found sibutramine in both. Neither label lists it. Sibutramine was the active ingredient in Meridia, a prescription weight-loss drug whose approval the FDA withdrew in 2010 after … Read more
A weight-loss supplement sold directly to consumers online has been recalled nationwide after FDA laboratory testing found two undeclared drugs inside the same box. The daytime tablets of Lipofit Extreme Fat Burner 2.0 contained fluoxetine, a prescription antidepressant. The nighttime tablets contained 2,4-dinitrophenol, a substance the FDA describes as a pesticide, dye, wood preservative and … Read more